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Introduction. Cutaneous foot melanoma is rare, challenging to manage, and not adequately examined in the literature. This study
evaluated the prognostic variables and surgical management of foot melanoma. Materials and Methods. Foot melanoma cases
managed at an academic center from 1985 to 2010 were retrospectively reviewed. Results. 46 patients were identified with a
broad range of demographic characteristics. Overall recurrence was 32.6%: 19% acral lentiginous, 57% nodular, 66% superficial
spreading, 30% melanoma unspecified, 50% severely atypical; 53% ulcerated, 23% nonulcerated; 29% on the dorsum of the foot,
17% heel, 60% ankle, 22% toe, 50% plantar; 0% <1 mm thick, 47% 1–4 mm, 33% >4 mm. 13 had positive nodes, 4 (31%)
of whom recurred. Prognostic factors and recurrence did not correlate, and survival was 96% with a median followup of 91
months. Conclusions. Aggressive management of foot melanoma may result in excellent long-term survival even following disease
recurrence.

1. Introduction
Malignant melanoma represents a major public health concern worldwide and the annual incidence has been steadily
rising since 1935 [1]. Approximately 3–5% of all cutaneous
melanomas arise in the foot, and foot melanoma poses a
challenge to clinicians who must balance adequate oncologic
resection with preservation of limb function [2]. When
margins smaller than recommended have been performed to
avoid amputation or skin grafting, the reported recurrence
rates have also been many times higher than at other
sites [3]. The literature has not adequately evaluated the
prognostic variables that guide the surgical management of
foot melanoma, as recommendations are based on studies
on melanoma arising on the trunk and elsewhere on the
extremities [4, 5].
Historically, clinicians have focused on clinical factors,
histology, anatomic location, and the presence or absence
of metastatic disease to determine the prognosis of patients
with melanoma [3, 6]. Pathologic variables include Breslow
thickness, Clark’s level of invasion, mitotic index, presence

of tumor infiltrating lymphocytes, ulceration, bleeding, and
lymph node status [4, 5]. Because of the more vertical
growth pattern of acral lentiginous and nodular melanomas
compared to the more radial growth pattern of superficial
spreading melanoma on pathology, it has been thought that
superficial spreading melanoma confers a better prognosis
[3]. Historically, in response to Paget’s soil versus seed theory,
Ewing argued that the anatomic location of a neoplasm
determines prognosis because of the variable density of soft
tissues, blood, and lymphatic vessels [3]. In the foot, this
argument was even further applied to distinguish between
the prognosis of melanoma arising on the dorsum of the foot
versus the plantar aspect of the foot based on the variable
thickness of the skin and the variable density of vascular
and lymphatic networks between these sites [3]; however,
there is no consensus in the literature regarding the variables
that predict prognosis and, therefore, which should guide the
management of foot melanoma.
The literature does not adequately analyze the prognostic
variables, management, and outcomes of foot melanoma.
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Figure 1: The demographics of the patients by age distribution.

Because foot melanoma is so rare, many publications
combine melanoma of the foot with the hand, leg, or thigh
for statistical purposes. Even papers that focus solely on the
foot are often confounding in their conclusions because they
combine cutaneous melanoma with subungual melanoma.
In addition, there has been great variability in the factors
that the literature has analyzed, even in regard to such
clinically significant considerations as pathology, thickness,
lymph node status, metastasis, recurrence, and survival. This
retrospective study was performed to review the prognostic
variables, management, and outcomes of foot melanoma to
try to arrive at surgical guidelines.
Patients treated for cutaneous melanoma of the foot
from 1985 to 2010 at the Virginia Commonwealth University Health System were retrospectively reviewed for
demographic data, histology, anatomic location, Breslow
thickness, mitotic index, ulceration, operation, surgical margin, lymph node status, location of recurrence, disease-free
survival, and overall survival. The Virginia Commonwealth
University Institutional Review Board granted approval for
this study, and this study complied with all guidelines
for ethical research. Recurrence analysis was performed by
calculating and plotting the median cumulative function
using JMP8 software. Statistical analysis utilized logistic
regression to evaluate for significance.

2. Materials and Methods
3. Results
46 patients were treated for foot melanoma from 1985
to 2010. Patient followup was a median of 91 months, a
mean of 101 months, and ranged from 4 to 300 months.
Patients were followed for 3 months for the first 2 years,
then for 6 months until the 5th year, followed by yearly
thereafter. No patients were lost to follow up. Patients were
treated with wide local excision with primary closure or
skin grafting; amputation was performed when a lesser
procedure was unable to obtain an adequate margin and
leave a functioning foot. Lymphadenectomy was performed
when lymph node metastasis was detected clinically or by
sentinel node biopsy. Palliative debulking of wound, regional,

and distant recurrences was performed when appropriate.
No patients received adjuvant therapy.
The patient demographics, pathology, site of origin, and
surgical treatment were examined. Of the 46 patients, 15
were men and 31 were women. Age at diagnosis ranged from
16 to 99 years of age, with a median of 62 years (mean
59) (Figure 1). Ethnic distribution included 31 Caucasians,
12 African Americans, 1 Hispanic, and 2 others. The
pathologic demographics included 16 acral lentiginous, 10
unspecified, 9 superficial spreading, 7 nodular, 2 severely
atypical (melanoma which the pathologists could not further
classify), and 2 desmoplastic; 16 were ulcerated with a
median thickness of 2.38 mm (mean 4.9 mm) and a median
mitotic index of 2 per ten high power fields (mean 4).
Clark’s level of invasion was not uniformly reported in
these patients. The anatomic distribution included 17 on the
dorsum of the foot, 6 heel, 5 ankle, 9 toe, 8 plantar, and 1
webspace. 39 patients underwent wide local excision, 6 toe
amputation, 1 below knee amputation, and 20 underwent
sentinel lymph node biopsy or lymph node dissection. The
patients represented a broad distribution of demographic
characteristics, pathologic subtypes, and sites of origin.
The correlations between site of origin, pathologic
subtype, thickness, and mitotic index were examined. Acral
lentiginous, nodular, superficial spreading, unspecified,
severely atypical, desmoplastic, and ulcerated melanomas
were well distributed across the sites of origin (Figure 2(a)).
Similarly, there was a broad distribution of lesions by
thickness across the sites of origin (Figure 2(b)). The distribution of the average thickness by pathologic subtype is
shown (Figure 2(c)). Superficial spreading and unspecified
melanomas were thinner than other subtypes, and ulcerated lesions were thicker than nonulcerated lesions. The
distribution of the average mitotic index (mitoses/10 high
power fields) is shown (Figure 2(d)). In general, the thicker
the melanoma, the higher the mitotic index. Superficial
spreading had the highest mitotic index, while there was only
a minimal diﬀerence in the mitotic index between ulcerated
and non-ulcerated lesions.
The correlations between recurrence rate and site of
origin, pathologic subtype, mitotic index, average thickness,
surgical treatment, and lymph node status were examined.
The rate of recurrence by histologic subtype of melanoma is
shown (Figure 3(a)). There did not appear to be a correlation
between recurrence rate and histology or site of origin.
Similarly, there did not appear to be a correlation between
location of recurrence and histology, site of origin or thickness (Figure 3(b)), or mitotic index (Figure 3(c)); thickness
did not appear to correlate with location of recurrence, but
lesions that recurred were thicker than those that did not
recur (Figure 3(d)). The recurrence rates were 36% for wide
local excision, none for toe amputation, and 100% (1/1) for
below knee amputation. 65% of the patients who underwent
a sentinel lymph node biopsy or lymph node dissection had
positive lymph nodes. 30% of patients with positive lymph
nodes developed a recurrence. There did not appear to be
a correlation between recurrence rate and site of origin,
pathologic subtype, mitotic index, average thickness, surgical
treatment, and lymph node status.
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Figure 2: The distributions of pathology by anatomic site of origin (a), thickness by anatomic site of origin (b), thickness by pathology (c),
and mitotic index by pathology and thickness (d).
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Figure 3: The recurrence rate by prognostic factor (a), site of recurrence by prognostic factor (b), recurrence and site of recurrence by
mitotic index (c), and thickness (d).

In order to compare the recurrence rates among the
diﬀerent prognostic variables, the mean cumulative function
(MCF) of each population was calculated. MCF assigns
a cost to a population each time a recurrence occurs in
that population [7–9]. The MCF plots a cost curve for
a population over time [8, 9]. As more members of that
population develop recurrences, more cost accrues to the
population, and the curve becomes higher [8, 9]. The MCF
of one population can then be compared to the MCF of
another population, which thus allows for the comparison

of recurrence rates between populations [7–9]. In addition
to analyzing the absolute recurrence rate, MCF comparison
allows for comparing how the risk of recurrence in diﬀerent
populations changes over time [7–9]. This method was used
to evaluate how the risk of recurrence by each prognostic
variable changed over time and how they were compared to
each other and to the overall population as a whole.
MCF analysis was used to compare the risk of recurrence
by histologic subtype, site of origin, and thickness. The
MCFs for each histologic subtype are shown (Figure 4(a)).
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Figure 4: Recurrence analysis: the mean cumulative functions compared by pathology (a), anatomic site of origin (b), and thickness (c).

The risks of recurrence for nodular and severely atypical
melanomas were consistently high, for acral lentiginous
it was consistently low, and for unspecified melanoma
consistently intermediate throughout the follow-up period.
For the first 150 months of followup, superficial spreading
melanoma maintained a risk of recurrence similar to all
subtypes combined. However, beyond 150 months, the risk
of recurrence increased rapidly to approach the risk of
recurrence of nodular melanoma. Neither of the patients
with desmoplastic melanoma developed a recurrence and,
therefore, were not included in this analysis. The MCFs
for each site of origin are shown (Figure 4(b)). The risk
of recurrence for plantar lesions was consistently high, for
lesions on the dorsum and toe consistently intermediate, and

for lesions on the ankle and heel consistently low throughout
the follow-up period. The MCFs by thickness are shown
(Figure 4(c)). After 25 months lesions 1–4 mm thick had a
consistently high risk of recurrence, while after 75 months
lesions >4 mm had a consistently low risk of recurrence. Of
all the variables compared, nodular melanomas, site of origin
on the plantar surface of the foot, and a thickness of 1–
4 mm maintained the consistently highest risk of recurrence.
Lesions <1 mm thick did not recur and therefore were
not included in this analysis. Two patients died: one from
pneumonia at age 103, the other from melanoma at age
72, 297 and 22 months after being diagnosed with foot
melanoma, respectively. Overall survival was 96% with a 91month median followup.
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Table 1: A review of the literature on foot melanoma that shows whether cutaneous foot melanoma exclusively, histology, site of origin on
the foot, lymph node status, recurrence, overall survival, median followup, and average thickness were reported and analyzed.
Study

Foot only

Histology

Site

LNs

Booher and Pack,
1957 [3]

No

No

No

Yes

Keyhani, 1977 [17]

No

No

No

Yes

Magnus, 1977 [18]
Feibleman et al.,
1980 [12]
Sondergaard and
Olsen, 1980 [22]
Day Jr. et al.,
1981 [11]
Hughes et al.,
1985 [16]
Urist et al., 1985 [24]
Slingluﬀ Jr. et al.,
1990 [21]
Barnes et al.,
1994 [10]

No

No

No

No

No

Yes

No

Yes

No

Yes

Yes

Yes

Yes (29)

Yes

No

No

No

Yes

Yes

Yes

No

No

No

No

No

No

No

Yes

No

Yes

Yes

Yes

Fortin et al., 1995 [13]

No

No

Yes

Yes

Garbe et al., 1995 [14]
Tseng et al., 1997 [2]

No
No

No
Yes

No
No

No
Yes

Gray et al., 2006 [6]

No

Yes

No

Yes

No

Yes

No

No

No

No

No

Nagore et al.,
2006 [19]
Soudry et al.,
2008 [23]
Rex et al., 2009 [20]

Survival

Followup
(months)

Average
thickness
(mm)

Yes

192

No

Yes

60

No

Yes

216

No

No

60

No

Not assessed

Yes

120

No

Overall recurrence

No

60

No

Yes

<12

No

No

120

No

Yes

62

2.64

Yes

72

No

Recurrence
Wound, regional,
distant
Wound, regional,
distant
Not assessed
Wound, regional,
total

Wound, in-transit,
overall
Wound
Wound, regional,
distant skin, other
Not assessed
Wound, regional,
total
Not assessed
Wound, distant
Wound, regional,
distant

Yes

45

3.03

Yes
No

120
67

2.2
No

No

33

1.75

No

Not assessed

No

None

1.3

No

Yes

Overall recurrence

Yes

53

3.28

No

No

Wound,
satellite/in-transit,
regional, distant

Yes

50

2.8

4. Discussion
Foot melanoma is a rare disease which has not been adequately examined in the literature. From 1957 to 2010 only
one publication examined cutaneous foot melanoma alone
without confounding results by combining with subungual,
hand or other lower extremity primary sites (Table 1) [2,
3, 6, 10–24]. There has not been an adequate evaluation of
prognostic factors, such as histologic subtype, site of origin,
or even lymph node status. Because of the great variability
in reporting followup, thickness, recurrence, and survival
rates, it is diﬃcult to appropriately quantify recurrence and
survival analyses or draw conclusions.
This study reviewed 46 cutaneous foot melanoma patients with a broad distribution of demographic characteristics, histology, thicknesses, mitotic indexes, and sites of
origin. Although there were more cases of acral lentiginous
melanoma, it was not the predominant subtype as had been
historically thought of the acral sites [3]. There was a trend

for more superficial spreading melanomas to arise on the
dorsum of the foot (Figure 2(a)) and for thicker lesions to
have a higher mitotic index, but this was without statistical
significance (Figure 2(d)). There was no correlation between
histology, thickness, site of origin, or mitotic index (Figures 2(a)–2(d)), which had not been previously evaluated
(Table 1) [2, 3, 6, 10–24].
This study evaluated whether the absolute recurrence
rate, the site of recurrence (Figures 3(a)–3(d)), or the change
in recurrence rate over time correlated with prognostic
factors (Figures 4(a)–4(c)), which has not been previously
examined (Table 1) [2, 3, 6, 10–24]. None of the desmoplastic
(2, median followup 161.4 months) or <1 mm thick lesions
recurred (Figure 3(a)). There was no correlation between
histology, site of origin, lymph node status, thickness, or
mitotic index and overall recurrence rate (Figures 3(a)–
3(d)), although thickness approached significance (P =
0.0946). There was no significant correlation between recurrence rate or prognostic factor and site of recurrence, but
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wound recurrences had the highest mitotic index and lymph
node recurrences the greatest thickness (Figure 3(b)).
Although there was no significant correlation, there was a
trend for ulcerated lesions to have a higher average thickness
(Figure 2(c)) and mitotic index (Figure 2(c)) than nonulcerated melanomas and to have twice the recurrence rate
of non-ulcerated melanomas (Figure 3(a)). The implication
is that ulceration in combination with thickness and mitotic
index may worsen prognosis. For example, three of the
four acral lentiginous melanomas that recurred were also
ulcerated. Although there was no significant correlation,
there was a trend for ankle and plantar melanomas to have
higher recurrence rates than other sites (Figure 3(a)). Plantar
melanomas accounted for one-third of all ulcerated lesions
(Figure 2(a)), and over 50% of ankle and plantar lesions were
>4 mm in thickness (Figure 2(b)). In contrast, only 2 of the
5 melanomas on the dorsum of the foot that recurred were
ulcerated, while 3 of the 4 plantar melanomas that recurred
were ulcerated.
Although superficial spreading melanomas had a
higher absolute recurrence rate than nodular melanomas
(Figure 3(a)), this did not occur until after 150 months
(Figure 4(a)). The implication is that superficial spreading
melanomas may have a better prognosis in terms of
recurrence initially, but over time the diﬀerence disappears.
This trend is an important consideration as most
publications had a median followup of much less than
150 months (Table 1) [2, 3, 6, 10–24]. Acral lentiginous,
unspecified melanomas, and severely atypical melanomas
consistently maintained low, intermediate, and high rates
of recurrences, respectively (Figure 4(a)). The implication
is that other subtypes may not behave in the same way
as superficial spreading melanomas, but unspecified and
severely atypical melanomas were not followed as long.
Recurrence rate by thickness changed over time, but
by site of origin the rate of recurrence remained the same
(Figures 4(b) and 4(c)). Although initially similar, after 75
months 1–4 mm thick melanomas had a high recurrence
rate and >4 mm thick a low recurrence rate (Figure 4(c)).
These data suggest that thicker melanomas recur earlier
than thinner melanomas which may have implications for
follow-up evaluations for both sets of patients. It should be
noted that previous publications did not indicate the followup times for diﬀerent prognostic factors or perform such
recurrence analyses (Table 1) [2, 3, 6, 10–24]. The overall
survival was 96% at a median followup of 91 months.
Because of the excellent survival in these patients treated
over a 25-year period, no subgroup analyses could be
meaningfully performed, such as molecular, genetic, or
immunohistochemical analyses. In general, melanoma 5year survival has been reported as approximately 93% for
thin (<1 mm), 68% for intermediate thickness (1–4 mm),
and 42% for thick lesions (>4 mm) [1]. Although it has been
previously reported that melanoma in the extremity may
provide a worse prognosis than other sites and that other
prognostic factors, such as thickness, may predict survival
better than site alone, those studies combined it with disease
variants (Table 1) [2, 3, 6, 10–24]. Our results demonstrated
that even foot melanoma patients with poor prognostic
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factors such as thickness and ulceration had an excellent
survival compared to that reported for melanoma of the
trunk, hands, or extremities [1–3, 6, 10–24].
In conclusion, foot melanoma remains a challenge to
clinicians who must balance oncologic resection against
preserving limb function. A review of the literature since
1957 reveals that there has not been an adequate analysis of
prognostic factors to guide management. This study focused
exclusively on patients with cutaneous foot melanoma
treated over a 25-year period to comprehensively examine
the prognosis and management of this rare disease. Although
there were no statistically significant correlations between
disease free survival and prognostic variables, only trends,
survival was 96% at a median followup of 91 months.
Therefore, patients with foot melanoma appear to have an
excellent long-term survival even if they develop recurrent
disease.
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